原始型与现行型肉毒杆菌毒素治疗颈部肌张力障碍的疗效及免疫原性比较。
Comparison of efficacy and immunogenicity of original versus current botulinum toxin in cervical dystonia.
作者信息
Jankovic J, Vuong K D, Ahsan J
机构信息
Parkinson's Disease Center and Movement Disorders Clinic, Department of Neurology, Baylor College of Medicine, Houston, TX 77030, USA.
出版信息
Neurology. 2003 Apr 8;60(7):1186-8. doi: 10.1212/01.wnl.0000055087.96356.bb.
The authors compared 130 patients treated for cervical dystonia with original botulinum toxin (BTX) type A (Botox; Allergan, Inc., Irvine, CA), 42 of whom were exposed only to the original BTX type A used before 1998 (25 ng protein/100 units), and 119 treated only with the current BTX type A (5 ng of protein/100 units). Blocking antibodies were detected in 4 of 42 (9.5%) patients treated only with original BTX type A but in none of the 119 patients treated exclusively with current BTX type A (p < 0.004). The current preparation decreased the risk of antibody formation by a factor of six. The authors conclude that the low risk of antibody formation after current BTX type A treatment is related to lower protein load.
作者比较了130例接受原A型肉毒毒素（保妥适；艾尔建公司，加利福尼亚州欧文市）治疗的颈部肌张力障碍患者，其中42例仅接受1998年以前使用的原A型肉毒毒素（25纳克蛋白质/100单位）治疗，119例仅接受目前的A型肉毒毒素（5纳克蛋白质/100单位）治疗。仅接受原A型肉毒毒素治疗的42例患者中有4例（9.5%）检测到阻断抗体，而仅接受目前A型肉毒毒素治疗的119例患者中无一例检测到（p<0.004）。目前的制剂使抗体形成风险降低了六倍。作者得出结论，目前A型肉毒毒素治疗后抗体形成风险较低与蛋白质含量较低有关。
Zotero 插件